Asset profile
apitegromab
Monoclonal antibody
Evidence outlook · registrational
Spinal Muscular Atrophy: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-11-01.
Also in development:Obesity · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 61 same-indication; 9 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Apitegromab: this drug | Phase 3 | Monoclonal antibody | Activin/myostatin type II receptor | ||
| Bimagrumab | Phase 3 | Monoclonal antibody | Activin/myostatin type II receptor | ||
| Taldefgrobep Alfa | Phase 3 | Antibody-derived scaffold | Activin/myostatin type II receptor | ||
| LAE102 / LAE103 | Phase 1 | Monoclonal antibody | Activin/myostatin type II receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination) | ||
| Nusinersen (Spinraza) | Approved | RNA / oligonucleotide | — | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Orlistat (Xenical / Alli) | Approved | Small molecule | Pancreatic/gastric lipase | ||
| Phentermine / Topiramate (Qsymia) | Approved | Small molecule | Noradrenergic/anticonvulsant (combination) | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Setmelanotide (Imcivree) | Approved | Peptide | MC4R | ||
| Tirzepatide (Zepbound / Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| ARD-101 | Phase 3 | Small molecule | Bitter taste receptor (gut) |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.